Lyrica News and Research

RSS
Top-line results in Pfizer's Lyrica long term safety study for Generalized Anxiety Disorder

Top-line results in Pfizer's Lyrica long term safety study for Generalized Anxiety Disorder

Delaware district court upholds Pfizer's patents for LYRICA to treat pain and seizures

Delaware district court upholds Pfizer's patents for LYRICA to treat pain and seizures

Pfizer receives FDA approval for Lyrica to manage neuropathic pain associated with SCI

Pfizer receives FDA approval for Lyrica to manage neuropathic pain associated with SCI

Pfizer announces results from Lyrica clinical studies on fibromyalgia

Pfizer announces results from Lyrica clinical studies on fibromyalgia

Researchers find protein that controls neurotransmission: findings may lead to new drugs to treat neurological disorders

Researchers find protein that controls neurotransmission: findings may lead to new drugs to treat neurological disorders

Pfizer terminates Lyrica Phase 3 trial on neuropathic pain associated with HIV neuropathy

Pfizer terminates Lyrica Phase 3 trial on neuropathic pain associated with HIV neuropathy

Pfizer’s Lyrica Phase 3 study on pDPN fails to meet primary endpoint

Pfizer’s Lyrica Phase 3 study on pDPN fails to meet primary endpoint

Tonix completes TNX-102 pharmacokinetic study on fibromyalgia syndrome

Tonix completes TNX-102 pharmacokinetic study on fibromyalgia syndrome

AstraZeneca, Impax enter license agreement to commercialize Zomig in the U.S.

AstraZeneca, Impax enter license agreement to commercialize Zomig in the U.S.

Pfizer second-quarter revenues decrease 1% to $17.0 billion

Pfizer second-quarter revenues decrease 1% to $17.0 billion

Structural changes associated with frequent exacerbations identified in lungs of COPD patients

Structural changes associated with frequent exacerbations identified in lungs of COPD patients

Pfizer Lyrica Phase 3 study on Central Neuropathic Pain meets primary endpoint

Pfizer Lyrica Phase 3 study on Central Neuropathic Pain meets primary endpoint

Ideal psychotropic drug may cause physical dependence

Ideal psychotropic drug may cause physical dependence

EvaluatePharma data shows poor R&D productivity measures both in quality, quantity

EvaluatePharma data shows poor R&D productivity measures both in quality, quantity

New research: Fluid retention may explain drugs' risk of strokes and heart attacks

New research: Fluid retention may explain drugs' risk of strokes and heart attacks

Catalyst’s CPP-115 improves retinal safety profile than vigabatrin

Catalyst’s CPP-115 improves retinal safety profile than vigabatrin

Pfizer announces approval of Lyrica capsules for peripheral neuropathic pain

Pfizer announces approval of Lyrica capsules for peripheral neuropathic pain

New epilepsy drugs give more options, but make treatment decisions more complex: Epilepsy specialist

New epilepsy drugs give more options, but make treatment decisions more complex: Epilepsy specialist

FDA grants orphan-drug designation to Catalyst's CPP-115 investigational drug

FDA grants orphan-drug designation to Catalyst's CPP-115 investigational drug

Study demonstrates effectiveness of pre-emptive pain management protocol using pregabalin in urologic surgery

Study demonstrates effectiveness of pre-emptive pain management protocol using pregabalin in urologic surgery